<DOC>
	<DOC>NCT02154347</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with insulin in patients with type 2 Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral hypoglycemic agent.</brief_summary>
	<brief_title>Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<criteria>Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start Patients whose HbA1c at the time of an observation term start is 7.5% or more and less than 10.0% Type 1 Diabetes Mellitus Patients with serious diabetic complications and other serious complications</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>HbA1c</keyword>
</DOC>